HSIC vs. ROIV, RGEN, EHC, EXAS, TFX, CTLT, CHE, QGEN, GMED, and ELAN
Should you be buying Henry Schein stock or one of its competitors? The main competitors of Henry Schein include Roivant Sciences (ROIV), Repligen (RGEN), Encompass Health (EHC), Exact Sciences (EXAS), Teleflex (TFX), Catalent (CTLT), Chemed (CHE), Qiagen (QGEN), Globus Medical (GMED), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector.
Henry Schein (NASDAQ:HSIC) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.
96.6% of Henry Schein shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 1.1% of Henry Schein shares are held by company insiders. Comparatively, 4.6% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Henry Schein has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.
Henry Schein has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
Henry Schein received 325 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.00% of users gave Roivant Sciences an outperform vote while only 51.54% of users gave Henry Schein an outperform vote.
Henry Schein currently has a consensus price target of $81.73, indicating a potential upside of 9.95%. Roivant Sciences has a consensus price target of $16.90, indicating a potential upside of 48.12%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Roivant Sciences is more favorable than Henry Schein.
Roivant Sciences has a net margin of 3,624.14% compared to Henry Schein's net margin of 3.12%. Henry Schein's return on equity of 13.51% beat Roivant Sciences' return on equity.
In the previous week, Henry Schein had 22 more articles in the media than Roivant Sciences. MarketBeat recorded 26 mentions for Henry Schein and 4 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.59 beat Henry Schein's score of 0.15 indicating that Roivant Sciences is being referred to more favorably in the news media.
Summary
Roivant Sciences beats Henry Schein on 10 of the 18 factors compared between the two stocks.
Get Henry Schein News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Henry Schein Competitors List
Related Companies and Tools
